Drug
Tak 831
Tak 831: highest development phase Phase 2, developed by Neurocrine Biosciences. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-831 NCT03214588 | Phase 2 | Friedreich Ataxia |
| TAK-831 Oral Suspension NCT02566759 | Phase 1 | Schizophrenia, Cerebellar Ataxia |
Latest
No recent events.
Follow Tak 831 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.